Navigation Links
Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
Date:12/16/2009

FORT WORTH, Texas, Dec. 16 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that its Resorbable Orthopedics operating subsidiary is moving toward productization of its patented orthopedic bone void fillers. The company currently anticipates products to be introduced in Q3 2010, to the bio-products market, estimated to be a multi-billion dollar international market.

"Resorbable Orthopedics has patented technologies that include a resorbable bone wax and a delivery system for orthopedic bone void fillers that were previously unheard of. Orthopedic disorders are expanding internationally into a multi-billion dollar market," said Barry Constantine, founder of Resorbable Orthopedics LLC. "These new era biotechnology products are well timed solutions in a healthcare environment where there is a great need for safer and more affordable solutions to manage bone wound healing and thereby offer a better quality of life at an affordable price. Market entry is expected in 3rd quarter 2010 subject to initiation and completion of certain medical certifications."

"Over the past year we have assembled a national sales force of over 40 independent representatives as well as assembled an extensive international distribution channel for our core CellerateRx® product which targets an international market in excess of 2 billion dollars" stated WNDM CEO Scott Haire. "WNDM has acquired Resorbable Orthopedics to seek to gain a foothold within the international bioproducts market by utilizing our demand side marketing program and extensive WNDM infrastructure; Resorbable's orthopedic biomaterials products complement WNDM's existing proven CellerateRx wound management products and expands the company's biomaterials product portfolio."

For Wound Management Technologies Shareholder Information please call 954-357-
'/>"/>

SOURCE Wound Management Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
3. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
5. Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial
6. Wound Management Technologies, Inc. Announces Evidence Based Study
7. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
10. New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds
11. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Women everywhere ... infections are not only uncomfortable, they,re often also embarrassing ... plans. pH-D Feminine Health Support ( http://ph-defense.com ) is ... It is an all-natural, homeopathic product. ... common symptoms of vaginal infection. In many cases, the ...
(Date:9/17/2014)... LOS ANGELES and LEIPZIG, ... Inc. today announced that it has entered into ... for the development of antibody-based imaging agents to ... "Our collaboration with Novotectid expands ImaginAb,s capability to ... the immune-oncology and autoimmune disease areas. The ability ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
Breaking Medicine Technology:New Product from Vireo Systems: pH-D Feminine Health Support 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... Ind., Oct. 20, 2011 Hill-Rom Holdings, Inc., (NYSE: ... a management presentation at the Credit Suisse,s 2011 Healthcare ... p.m. ET. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at ...
... Oct. 20, 2011 The Academy of Managed ... Conference in Atlanta. The conference, Oct. 19-21, draws ... and features a wide range of programs and ... sessions, student pharmacist programming, networking events and other ...
Cached Medicine Technology:Academy of Managed Care Pharmacy Opens 2011 Educational Conference in Atlanta 2
(Date:9/17/2014)... In its latest blog post, Best Drug Rehabilitation , ... by during a stay in rehab can make a big ... highlighting a member of the therapeutic care team that is ... the country and around the world: dogs. , ... heart rate, and stress levels in recovering addicts,” commented Best ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Dennis Thompson ... News) -- Exposure in the womb to household chemicals ... of developing asthma, Columbia University researchers reported in a ... increased risk of developing asthma between age 5 and ... high levels of two phthalates (pronounced thal-ates), the researchers ...
(Date:9/17/2014)... 17, 2014Scientists at The Scripps Research Institute (TSRI) ... that is powerfully effective against vancomycin-resistant strains of ... vancomycin analog appears to have not one but ... bacteria probably cannot evolve resistance quickly. , "This ... will still be in clinical use a generation ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... HealthDay Reporter , TUESDAY, Oct. 26 (HealthDay News) ... could be prevented if people followed five simple healthy ... which would improve overall health as well -- include ... maintaining a healthy weight, the researchers say. "Even ...
... respond to hormonal changes and inflammation has been awarded ... five-year study. The research programme at the National ... is led by Professor Julian Davis, a consultant endocrinologist ... of Manchester,s Developmental Biomedicine Research Group. He is ...
... Professor Zhipeng Wu has invented a portable scanner based on radio ... presence of tumours malignant and benign in the breast ... breast cancer detection has been proven by researchers in the US, ... few minutes for an image to be produced, and this had ...
... is not considered effective treatment for KRAS (a gene)-mutated ... colorectal cancer not responding to chemotherapy and a certain ... had longer overall and progression-free survival than patients with ... 27 issue of JAMA . "Recent ...
... TUESDAY, Oct. 26 (HealthDay News) -- Children who survive ... on, a new study suggests. The findings highlight ... among childhood cancer survivors, the researchers said. "Current ... cancer, but we know that many cancer therapies -- ...
... 26 (HealthDay News) -- Primary care doctors earn the ... one reason for U.S. medical students, declining interest in ... at the wages of 6,381 physicians providing patient care ... primary care; surgery; internal medicine and pediatric subspecialties; and ...
Cached Medicine News:Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 2Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 3Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:Portable breast scanner allows cancer detection in the blink of an eye 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2Health News:Childhood Cancer Survivors Risk Future GI Problems 2Health News:Primary Care MDs at Low End of Pay Scale, Study Finds 2
... androgen secreted into the blood. In males, ... of the testes; in females ca. 50% ... of androstenedione, ca. 25% from the ovary ... The Testosterone ELISA KIT is based on ...
Microalbumin EIA Lipid / Protein Quantification 024-IDC-12...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: